Partner Headlines - CPHD

  1. UPDATE: ISI Group Upgrades Cepheid

    Benzinga
  2. CEPHEID

    IBD
  3. LinkedIn, TripAdvisor, Google: Top Manager's Ideas

    IBD
  4. Alexion Takes Off On Outlook

    IBD
  5. Three Medical Tech Names To Watch In Healthcare Space

    IBD
  6. Align Leads Three Top-Rated Medical Equipment Stocks

    IBD
  7. UPDATE: JMP Securities Initiates Coverage on Cepheid on Market ...

    Benzinga
  8. Five Medical Stocks Leaders Trade Near New Highs

    IBD
  9. ViroPharma Gets Bought Out; Medicines Clears Entry

    IBD
  10. UPDATE: ISI Group Downgrades Cepheid on Key Drivers Constraining ...

    Benzinga
  11. Benzinga's Top Downgrades

    Benzinga
  12. UPDATE: Bank of America Downgrades Cepheid on Fair Valuation

    Benzinga
  13. Benzinga's Top Downgrades

    Benzinga
  14. Cepheid Reports Xpert MTB/RIF Categorized 'Moderate Complexity' ...

    Benzinga
  15. Cepheid Announces Board of Directors Changes

    Benzinga
  16. Cepheid's Chlamydia and N. Gonorrhoeae Test Categorized 'Moderate ...

    Benzinga
  17. Medtech Stocks Moving As Conference Makes Waves

    IBD
  18. Medtech Stocks Moving As Conference Makes Waves

    IBD
  19. Cepheid Offers Update on Xpert Test Availability, Sees Q4 Sales ...

    Benzinga
  20. UPDATE: Piper Jaffray Downgrades Cepheid to Neutral, Lowers PT

    Benzinga
  21. Oppenheimer Holdings Reiterates Outperform Rating, $43 PT on ...

    Benzinga
  22. Canaccord Genuity Reiterates Buy Rating, $50 PT on Cepheid

    Benzinga
  23. Cantor Fitzgerald Reiterates Hold Rating, $38 PT on Cepheid

    Benzinga
  24. US Stock Futures Down Ahead Of Economic Data

    Benzinga
  25. Stocks To Watch For December 28, 2012

    Benzinga
  26. UPDATE: Cepheid Wins FDA Clearance for Xpert CT/NG

    Benzinga
  27. UPDATE: Bank of America Initiates Cepheid at Buy on Prospects, ...

    Benzinga
  28. Look At That Base: If You Can't Name It, Don't Buy It

    IBD
  29. UPDATE: Goldman Sachs Downgrades Cepheid to Neutral on Lack of ...

    Benzinga
  30. Benzinga's Top Downgrades

    Benzinga
  31. Benzinga's Top Upgrades

    Benzinga
  32. CEPHEID Reports Operating Results (10-Q)

    GuruFocus
  33. UPDATE: Cantor Fitzgerald Maintains Cepheid at Hold on Analyst ...

    Benzinga
  34. UPDATE: Canaccord Genuity Reiterates Cepheid at Buy with $50 ...

    Benzinga
  35. Goldman Sachs Reiterates Buy Rating, $46 PT on Cepheid

    Benzinga
  36. UPDATE: ISI Group Reduces PT to $30.50 on Cepheid Post Analyst ...

    Benzinga
  37. Benzinga Mid-Afternoon Market Update

    Benzinga
  38. Stock Futures Point to Higher Open with Yahoo (YHOO) and Hewlett-Packard ...

    MarketIntelligenceCenter
  39. Benzinga Mid-Day Market Update

    Benzinga
  40. Mid-Morning Market Update

    Benzinga
  41. UPDATE: ISI Group Reduces PT to $32.50 on Cepheid Following Negative ...

    Benzinga
  42. Benzinga's Top Initiations

    Benzinga
  43. A Peek Into The Market Before The Trading Starts

    Benzinga
  44. UPDATE: JP Morgan Initiates Cepheid at Overweight on Growth Outlook

    Benzinga
  45. Benzinga's Top Initiations

    Benzinga
  46. Technology Sector Wrap

    FoxBusiness
  47. Technology Sector Wrap

    FoxBusiness
  48. Technology Sector Wrap

    FoxBusiness
  49. Analyst Downgrades: Cepheid, Intuitive Surgical, and Travelzoo

    SchaeffersResearch
  50. Cepheid Down 20% on Weak Guidance

    Benzinga
  51. CEPHEID (CPHD) CEO John L Bishop sells 40,201 Shares

    GuruFocus
  52. CEPHEID (CPHD) CEO John L Bishop sells 25,000 Shares

    GuruFocus
  53. CEPHEID (CPHD) EVP, CFO Andrew Miller sells 17,437 Shares

    GuruFocus
  54. A Peek Into The Market Before The Trading Starts

    Benzinga
  55. UPDATE: UBS Investment Research Upgrades Cepheid to Buy; Opportunistic ...

    Benzinga
  56. Benzinga's Top Downgrades With Color for May 14, 2012

    Benzinga
  57. UPDATE: GARP Research & Securities Downgrades Cepheid to Neutral; ...

    Benzinga
  58. Cepheid Earnings Miss Estimates; Stock Plummets

    IBD
  59. Cepheid Q1 Estimates Soft, But Outlook For Year Good

    IBD
  60. Zoll Deal, Intutive Surgical Lift Medical Equipment

    IBD
  61. Cepheid Stock Price Rises on Strong 2012 Sales Outlook

    IBD
  62. CEPHEID Reports Operating Results (10-K)

    GuruFocus
  63. CEPHEID (CPHD) Executive VP, COO Humberto Reyes sells 133,957 ...

    GuruFocus
  64. CEPHEID (CPHD) EVP, CFO Andrew Miller sells 62,062 Shares

    GuruFocus
  65. CEPHEID (CPHD) CEO John L Bishop sells 6,887 Shares

    GuruFocus
  66. Stocks Finish Week Split; Nasdaq, S&P 500 Higher

    IBD
  67. Stocks Stay Mixed; Under Armour Clears 50-Day

    IBD
  68. RBC Capital Upgrades Cepheid to Outperform

    Benzinga
  69. UPDATE: Credit Suisse Initiates Outperform, $40 Target on Cepheid

    Benzinga
  70. Analogic Earnings Preview: EPS Expected to Double

    Benzinga
Trading Center